UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

~~PURSUANT~~Pursuant TOto ~~SECTION~~Section 13 ORor 15(d) OFof the ~~THE~~Securities Exchange Act of 1934

~~SECURITIES~~Date ~~EXCHANGE~~of ~~ACT~~Report OF(Date ~~1934~~of earliest event reported): March 22, 2019

~~Date~~Pharmos ~~of report (date of earliest event reported): January 2, 2013~~Corporation

PHARMOS CORPORATION

(Exact name of registrant as specified in its charter)

Nevada	000-11550	036-~~11550~~3207413		~~36-3207413~~
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
	99 Wood Avenue South, Suite 302, Islin, NJ		08830
	(Address of principal executive offices)		(Zip code)

Registrant’s telephone number, including area code: (732) 452-9556

3609 Hammerkop Dr. North Las Vegas, NV	89084
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code (415) 841-3570

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ ¨ Soliciting material pursuant to Rule 14a-212 under the Exchange Act (17 CFR 240.14a-212)

□ ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~Indicate ~~4.01~~by ~~Changes~~check mark whether the registrant is an emerging growth company as defined in ~~Registrant’s~~Rule ~~Certifying~~405 ~~Accountant~~of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

OnEmerging growth ~~January 2, 2013, Friedman LLP (“Friedman”) resigned as the independent registered accounting firm for Pharmos Corporation (the “Company”).~~company ☐

~~Friedman’s~~If an ~~reports~~emerging ongrowth ~~the~~company, ~~financial~~indicate ~~statements~~by ~~for~~check ~~the~~mark ~~fiscal~~if ~~years~~the ~~ended~~registrant ~~December~~has ~~31,~~elected ~~2011 and 2010, did~~ not ~~contain~~to anuse ~~adverse~~the ~~opinion~~extended ortransition aperiod ~~disclaimer~~for complying ofwith ~~opinion,~~any ~~nor~~new ~~were they qualified~~ or ~~modified~~revised asfinancial toaccounting ~~uncertainty,~~standards ~~audit~~provided ~~scope~~pursuant orto ~~auditing~~Section ~~principles,~~13(a) ~~except~~of the ~~reports~~Exchange ~~included an explanatory paragraph related to the Company’s ability to continue as a going concern~~Act.☐

During the two fiscal years ended December 31, 2011 and 2010, and through the interim periods that Friedman reviewed in 2012, there were no disagreements with Friedman on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Friedman, would have caused it to make a reference to such disagreements in its report and there were no reportable events as defined in Item 304(a)(l)(v) of Regulation S-K.1

~~The~~Section ~~Company~~8 ~~has~~- ~~provided~~Other Friedman with a copy of the foregoing disclosures and requested that it furnish the Company with a letter addressed to the Securities and Exchange Commission (the “SEC”) stating whether or not it agrees with the above statements. A copy of such letter is filed as Exhibit 16.1 to this Current Report on Form 8-K.Events

Item 58.0201 ~~Departure~~Other ~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Events.

~~Also~~The asRegistrants’s ~~previously~~current contact ~~disclosed,~~information on November 15, 2012, Eric Fangmann was designated as the Acting President and Acting Chief Financial Officer of the Company. Mr. Fangmann, age 43, has been the Chief Financial Officer for Lloyd I. Miller, III for approximately two years. Prior to that time, Mr. Fangmann was an independent accounting and finance consultant who was principally engaged by either publicly traded or privately held entities to assist in independent analysis or agreed upon procedures. Mr. Fangmann is ~~not~~listed ~~currently being compensated by the Company for his services.~~below:

~~Item~~Address: ~~8.01 Other~~3609 ~~Events~~Hammerkop Dr., North Las Vegas, NV 89084

~~The~~Phone ~~Company~~number: ~~intends to file a Form 15 with the SEC in early January 2013 to effect the suspension of the Company’s reporting obligations under Section 13~~(a415) ~~and 15(d) of the Exchange Act. Upon the filing of the Form 15, the Company’s obligation to file periodic and current reports with the SEC, including Forms 10~~841-~~K, 10-Q and 8-K, will be immediately suspended.~~3570

~~Item 9~~Email: pharmoscorp@hotmail.~~01 Financial Statements and Exhibits.~~com

~~Exhibit~~The NoRegistrant’s President, Secretary, Chief Financial Officer, Chief Executive Officer and Chairman of the Board of Directors is Richard Chiang, who may be reached at the Registrant’s address above. ~~Description~~

~~16.1 Letter from Friedman LLP to the SEC.~~SIGNATURES

2Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~SIGNATURES~~Pharmos Corporation (Registrant) Date: March 22, 2019 By: /s/ Richard Chiang Richard Chiang Chief Executive Officer

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~2

	PHARMOS CORPORATION
Date: January 2, 2013	By:	/s/ Eric W. Fangmann
		Eric W. Fangmann
		Acting President and Acting Chief Financial Officer

EXHIBIT INDEX

Exhibit No. Description

16.1 Letter from Friedman LLP to the SEC.

Filing Compare · PHARMOS CORP